×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
EXEL – exelixis, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
EXEL
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/2
10:03 am
exel
Exelixis (NASDAQ:EXEL) was given a new $49.00 price target on by analysts at Morgan Stanley.
Medium
Report
Exelixis (NASDAQ:EXEL) was given a new $49.00 price target on by analysts at Morgan Stanley.
2/2
08:12 am
exel
Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer [Yahoo! Finance]
Low
Report
Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer [Yahoo! Finance]
2/2
08:00 am
exel
Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
Medium
Report
Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
2/2
07:18 am
exel
Alterome Therapeutics Appoints Leo Faoro, MD, MBA, as Chief Medical Officer [Yahoo! Finance]
Medium
Report
Alterome Therapeutics Appoints Leo Faoro, MD, MBA, as Chief Medical Officer [Yahoo! Finance]
2/1
08:26 pm
exel
Exelixis Files Zanzalintinib With FDA As Valuation Signals Upside Potential [Yahoo! Finance]
Low
Report
Exelixis Files Zanzalintinib With FDA As Valuation Signals Upside Potential [Yahoo! Finance]
2/1
10:33 am
exel
Assessing Exelixis (EXEL) Valuation After Recent Share Price Volatility [Yahoo! Finance]
Low
Report
Assessing Exelixis (EXEL) Valuation After Recent Share Price Volatility [Yahoo! Finance]
2/1
07:53 am
exel
Is Exelixis (EXEL) Using Zanzalintinib To Redefine Its Post-Cabometyx Oncology Strategy? [Yahoo! Finance]
Low
Report
Is Exelixis (EXEL) Using Zanzalintinib To Redefine Its Post-Cabometyx Oncology Strategy? [Yahoo! Finance]
1/31
07:22 pm
exel
2 Stocks That Could Soar This Year [Yahoo! Finance]
Low
Report
2 Stocks That Could Soar This Year [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/16
07:03 pm
exel
Form 4 EXELIXIS, INC. For: Jan 15 Filed by: Haley Patrick J.
Low
Report
Form 4 EXELIXIS, INC. For: Jan 15 Filed by: Haley Patrick J.
1/16
07:03 pm
exel
Form 4 EXELIXIS, INC. For: Jan 15 Filed by: Aftab Dana
Low
Report
Form 4 EXELIXIS, INC. For: Jan 15 Filed by: Aftab Dana
1/16
07:03 pm
exel
Form 4 EXELIXIS, INC. For: Jan 15 Filed by: Senner Christopher J.
Low
Report
Form 4 EXELIXIS, INC. For: Jan 15 Filed by: Senner Christopher J.
1/16
07:03 pm
exel
Form 4 EXELIXIS, INC. For: Jan 15 Filed by: MORRISSEY MICHAEL
Low
Report
Form 4 EXELIXIS, INC. For: Jan 15 Filed by: MORRISSEY MICHAEL
1/12
04:23 pm
exel
Form 8-K EXELIXIS, INC. For: Jan 11
Low
Report
Form 8-K EXELIXIS, INC. For: Jan 11
1/5
06:06 pm
exel
Form SCHEDULE 13D/A EXELIXIS, INC. Filed by: Farallon Capital Partners, L.P.
Medium
Report
Form SCHEDULE 13D/A EXELIXIS, INC. Filed by: Farallon Capital Partners, L.P.
12/12
06:08 pm
exel
Form 144 EXELIXIS, INC. Filed by: Haley Patrick J.
Low
Report
Form 144 EXELIXIS, INC. Filed by: Haley Patrick J.
12/5
06:51 pm
exel
Form 4 EXELIXIS, INC. For: Dec 03 Filed by: Hefti Brenda
Medium
Report
Form 4 EXELIXIS, INC. For: Dec 03 Filed by: Hefti Brenda
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/17
Form 4 EXELIXIS, INC. For: Apr 15 Filed by: SCANGOS GEORGE A
21.5%
6/20 Exelixis lower after IMspire170 fails to meet primary endpoint [Seeking Alpha] 9.0%
4/22 Form 4 EXELIXIS, INC. For: Apr 20 Filed by: Haley Patrick J. 7.6%
4/3 Form 4 EXELIXIS, INC. For: Apr 03 Filed by: WYSZOMIERSKI JACK L 6.7%
1/13 Form 8-K EXELIXIS, INC. For: Jan 12 6.6%
1/7 Exelixis, Inc. (NASDAQ: EXEL) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 6.1%
7/15 Exelixis Updates Phase 1b COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Patients With Advanced Solid Tumors 6.0%
11/13 Exelixis, Inc. (NASDAQ: EXEL) is now covered by analysts at Bank of America Corp. They set a "buy" rating on the stock. 6.0%
4/21 Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at Barclays PLC. They now have a $30.00 price target on the stock. 5.6%
1/13 Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at Bank of America Corp. They now have a $21.00 price target on the stock, down previously from $22.00. 4.9%
6/20 Exelixis lower after IMspire170 fails to meet primary endpoint [Seeking Alpha] 9.0%
4/22 Form 4 EXELIXIS, INC. For: Apr 20 Filed by: Haley Patrick J. 7.6%
4/3 Form 4 EXELIXIS, INC. For: Apr 03 Filed by: WYSZOMIERSKI JACK L 6.7%
1/13 Form 8-K EXELIXIS, INC. For: Jan 12 6.6%
1/7 Exelixis, Inc. (NASDAQ: EXEL) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 6.1%
7/15 Exelixis Updates Phase 1b COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Patients With Advanced Solid Tumors 6.0%
11/13 Exelixis, Inc. (NASDAQ: EXEL) is now covered by analysts at Bank of America Corp. They set a "buy" rating on the stock. 6.0%
4/21 Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at Barclays PLC. They now have a $30.00 price target on the stock. 5.6%
1/13 Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at Bank of America Corp. They now have a $21.00 price target on the stock, down previously from $22.00. 4.9%
TOP News Decliners
10/30
Exelixis Announces Third Quarter 2019 Financial Results and Provides Corporate Update
-14.9%
3/13 Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at William Blair. -13.8%
1/24 Exelixis up 1% premarket on Cabometyx data in liver cancer [Seeking Alpha] -8.7%
7/31 Form 8-K EXELIXIS, INC. For: Jul 31 -6.5%
10/3 Form 4 EXELIXIS, INC. For: Oct 01 Filed by: Schwab Gisela -6.3%
4/9 Form DEF 14A EXELIXIS, INC. For: May 20 -5.2%
4/29 Form 4 EXELIXIS, INC. For: Apr 27 Filed by: MORRISSEY MICHAEL -5.0%
12/5 How Should Investors React To Exelixis, Inc.'s (NASDAQ:EXEL) CEO Pay? [Yahoo! Finance News] -4.6%
3/10 Exelixis, Inc. (EXEL) CEO Mike Morrissey Presents at Barclays Global Healthcare Conference 2020 (Transcript) [Seeking Alpha] -4.6%
12/6 Hedge Funds Are Warming Up To Exelixis, Inc. (EXEL) [Yahoo! Finance News] -4.5%
3/13 Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at William Blair. -13.8%
1/24 Exelixis up 1% premarket on Cabometyx data in liver cancer [Seeking Alpha] -8.7%
7/31 Form 8-K EXELIXIS, INC. For: Jul 31 -6.5%
10/3 Form 4 EXELIXIS, INC. For: Oct 01 Filed by: Schwab Gisela -6.3%
4/9 Form DEF 14A EXELIXIS, INC. For: May 20 -5.2%
4/29 Form 4 EXELIXIS, INC. For: Apr 27 Filed by: MORRISSEY MICHAEL -5.0%
12/5 How Should Investors React To Exelixis, Inc.'s (NASDAQ:EXEL) CEO Pay? [Yahoo! Finance News] -4.6%
3/10 Exelixis, Inc. (EXEL) CEO Mike Morrissey Presents at Barclays Global Healthcare Conference 2020 (Transcript) [Seeking Alpha] -4.6%
12/6 Hedge Funds Are Warming Up To Exelixis, Inc. (EXEL) [Yahoo! Finance News] -4.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: